Glycosylation of Recombinant Antibody Therapeutics

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Biotechnology progress (Print)

• Publication date

  2008-09-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1021/bp040016jPMID 15903235
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gal alpha 1,3Gal expression on porcine pancreatic islets, testis, spleen, and thymus.

  2004cited by this paper
• V Region Carbohydrate and Antibody Expression1

  2004cited by this paper
• Galα1,3Gal expression on porcine pancreatic islets, testis, spleen, and thymus

  2004cited by this paper
• Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.

  2004cited by this paper
• The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity*

  2003cited by this paper
• Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.

  2003cited by this paper
• Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa‐associated lymphoid tissue lymphoma

  2003cited by this paper
• Release of pig leukocytes during pig kidney perfusion and characterization of pig lymphocyte carbohydrate xenoantigens

  2003cited by this paper
• [The alpha-gal epitope (Gal alpha 1-3 Gal beta 1-4 GlcNAc-R) in xenotransplantation].

  2003cited by this paper
• Interaction sites on human IgG-Fc for FcγR: current models

  2002cited by this paper
• Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity*

  2002cited by this paper
• Interaction sites on human IgG-Fc for FcgammaR: current models.

  2002cited by this paper
• Glycosylation of human IgG antibodies: Relevance to therapeutic applications

  2002cited by this paper
• Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding.

  2001cited by this paper
• The Structure of a Human Type III Fcγ Receptor in Complex with Fc*

  2001cited by this paper
• Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding*

  2001cited by this paper
• High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*

  2001cited by this paper
• The α-Gal epitope (Galα1-3Galβ1-4GlcNAc-R) in xenotransplantation.

  2001cited by this paper
• Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.

  2001cited by this paper
• Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I.

  2000cited by this paper
• The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex

  2000cited by this paper
• Glycoprotein folding in the endoplasmic reticulum: a tale of three chaperones?

  2000cited by this paper
• Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc

  2000cited by this paper
• The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.

  2000cited by this paper
• The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex.

  2000cited by this paper
• Expression and characterization of truncated forms of humanized L243 IgG1

  2000cited by this paper
• Effect of somatic hypermutation on potential N-glycosylation sites in human immunoglobulin heavy chain variable regions.

  2000cited by this paper
• Antigen Binding of an Ovomucoid-specific Antibody is Affected by a Carbohydrate Chain Located on the Light Chain Variable Region

  2000cited by this paper
• Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-->6) dextran antibody.

  1999cited by this paper
• Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding.

  1999cited by this paper
• Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells.

  1999cited by this paper
• Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

  1999cited by this paper
• Degradation of Misfolded Endoplasmic Reticulum Glycoproteins in Saccharomyces cerevisiae Is Determined by a Specific Oligosaccharide Structure

  1998cited by this paper
• Xenoantigens and xenoantibodies

  1998cited by this paper
• IgG‐Fc‐mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation

  1998cited by this paper
• Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody—antigen interaction

  1997cited by this paper
• Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains.

  1996cited by this paper
• Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients.

  1996cited by this paper
• Glycosylation of the variable region of immunoglobulin G--site specific maturation of the sugar chains.

  1995cited by this paper
• Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein

  1995cited by this paper
• Three-dimensional elution mapping of pyridylaminated N-linked neutral and sialyl oligosaccharides.

  1995cited by this paper
• Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG.

  1995cited by this paper
• Crystal structure of the complex of rat neonatal Fc receptor with Fc

  1994cited by this paper
• The glycosylation of antibody molecules: functional significance.

  1993cited by this paper
• Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody.

  1993cited by this paper
• Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution.

  1981cited by this paper

• Antigen binding triggers long-range conformational changes in monoclonal antibodies

  2026cites this paper
• Unlabeled NMR Approach with Site-Specific Methyl Assignments for Structural Evaluation of the IgG1 Fc Region.

  2026cites this paper
• On the achievable consistency of glycan distribution in biomanufacturing of therapeutic mAbs

  2026cites this paper
• Targeting the epidermal growth factor receptor using IgM antibodies: toward next generation cancer immunotherapy

  2026cites this paper
• The importance of IgG N-glycosylation in Health, Disease, and Neonatal hemochromatosis

  2025cites this paper
• Fucosylation limits ADCC in clinically used anti-RhD monoclonal antibodies.

  2025cites this paper
• Fab N-Glycosylation in IgG: Implications in Physiological and Pathological Immune Regulation

  2025cites this paper
• Enhancing the Total Terminal Galactosylation of CHO Cell-Derived TNF-α Blocker-IgG1 Monoclonal Antibody Using Time-Dependent Galactose Supplementation

  2025influential citation
• Feasibility of Rapid Regulatory Differentiation of TNF Receptor 2-Fc Fusion Protein Products from Various Manufacturers in the Chinese Market Using a Novel Mass Spectrometry-Based Multi-attribute Method (MAM).

  2025cites this paper
• Variable domain glycosylation as a marker and modulator of immune responses: Insights into autoimmunity and B-cell malignancies.

  2025cites this paper
• The Contribution of Immunoglobulin G to Inflammation is Regulated by The Site of Production via Glycosylation

  2025cites this paper
• Effect of N-Glycan Profiles on Binding Affinity of Diagnostic Antibody Produced by Hybridomas in Serum-Free Suspension

  2025cites this paper
• Perspective view of allogeneic IgG tumor immunotherapy

  2024cites this paper
• A multimodal digital microfluidic testing platform for antibody-producing cell lines.

  2024cites this paper
• Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivo

  2024cites this paper
• Process Intensification by Inoculating Antibody Production Bioreactors Directly from Cryovials

  2024cites this paper
• Rapid Mass Spectrometry-Based Multiattribute Method for Glycation Analysis with Integrated Afucosylation Detection Capability.

  2024cites this paper
• Systematic Preparation of a 66-IgG Library with Symmetric and Asymmetric Homogeneous Glycans and Their Functional Evaluation

  2024cites this paper
• Discovery and Characterization of Unusual O‐Linked Glycosylation of IgG4 Antibody Using LC‐MS

  2024cites this paper
• Scaling Fed-Batch and Perfusion Antibody Production Processes in Geometrically Dissimilar Stirred Bioreactors

  2024cites this paper
• Structure-Based High-Efficiency Homogeneous Antibody Platform by Endoglycosidase Sz Provides Insights into Its Transglycosylation Mechanism

  2024cites this paper
• Cell-culture process optimization via model-based predictions of metabolism and protein glycosylation.

  2023cites this paper
• LC/MS Assessment of Glycoform Clearance of a Biotherapeutic mAb in Rabbit Ocular Tissues.

  2023cites this paper
• The role of glycan characterisation in ATMP development and evaluation

  2023cites this paper
• Modulating antibody effector functions by Fc glycoengineering.

  2023cites this paper
• Multi-Attribute Monitoring Method for Process Development of Engineered Antibody for Site-Specific Conjugation

  2023cites this paper
• Blueprint for antibody biologics developability

  2023cites this paper
• Efficient optimization of time‐varying inputs in a fed‐batch cell culture process using design of dynamic experiments

  2023cites this paper
• Immunoglobulin G glycans - biomarkers and molecular effectors of aging.

  2022cites this paper
• Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies

  2022cites this paper
• Sialylation as an Important Regulator of Antibody Function

  2022cites this paper
• Oligoclonal bands: An immunological and clinical approach.

  2022cites this paper
• Fast and Ultrasensitive Glycoform Analysis by Supercritical Fluid Chromatography–Tandem Mass Spectrometry

  2022cites this paper
• Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments.

  2022cites this paper
• A glyco-engineering approach for site-specific conjugation to Fab glycans

  2022cites this paper
• Glycosylation site Asn168 is important for slow in vivo clearance of recombinant human diamine oxidase heparin-binding motif mutants.

  2022cites this paper
• Development of a CHO cell line for stable production of recombinant antibodies against human MMP9

  2022cites this paper
• Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry

  2022cites this paper
• Glikoznanost-nova smjernica u suvremenom

  2021cites this paper
• Developing a medium combination to attain similar glycosylation profile to originator by DoE and cluster analysis method

  2021cites this paper
• Physicochemical characterization of monoclonal antibodies

  2021cites this paper
• Routine Analysis of N-Glycans Using Liquid Chromatography Coupled to Routine Mass Detection.

  2021cites this paper
• Multiattribute Monitoring of Antibody Charge Variants by Cation-Exchange Chromatography Coupled to Native Mass Spectrometry.

  2021cites this paper
• Glycosylation analysis

  2021cites this paper
• Evaluating N-Glycosylation of a Therapeutic Monoclonal Antibody Using UHPLC-FLR-MS with RapiFluor-MS Labeling.

  2021cites this paper
• A study of the possible role of Fab-glycosylated IgG in tumor immunity

  2021cites this paper
• Empirical and Rational Design of T Cell Receptor-Based Immunotherapies

  2021cites this paper
• The current status of anti-citrullinated protein antibodies and citrullinated protein-reactive B cells in the pathogenesis of rheumatoid arthritis

  2021cites this paper
• Human IgG Glycosylation in Inflammation and Inflammatory Disease

  2021cites this paper
• The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies

  2021cites this paper
• APB-F1, a long-acting feline granulocyte colony-stimulating factor fusion protein, created by exploiting FL335, a chimeric Fab specific for feline serum albumin.

  2021cites this paper
• Preparation and biological activities of anti-HER2 monoclonal antibodies with multi-branched complex-type N-glycans.

  2021cites this paper
• Current status and future prospects for ion-mobility mass spectrometry in the biopharmaceutical industry.

  2021cites this paper
• IgG N-glycans.

  2021cites this paper
• Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System

  2021cites this paper
• Fast and ultra-sensitive glycoform analysis by supercritical fluid chromatography-tandem mass spectrometry

  2021cites this paper
• Bispecific antibodies: A promising entrant in cancer immunotherapy

  2021cites this paper
• Desalting Paper Spay Mass Spectrometry (DPS-MS) for Rapid Detection of Glycans and Glycoconjugates.

  2021cites this paper
• Multiplexed Comparative Analysis of Intact Glycopeptides using Electron-Transfer Dissociation (ETD) and Synchronous Precursor Selection (SPS) -based Triple-Stage Mass Spectrometry (MS3).

  2020cites this paper
• Index

  2020cites this paper
• Expression, Purification, and Evaluation of Anti-IL-2Rα Antibody Secreted by Leishmania tarentolae

  2020cites this paper
• Perfusion Cell Culture Processes for Biopharmaceuticals

  2020cites this paper
• Role of NMR in High Ordered Structure Characterization of Monoclonal Antibodies

  2020cites this paper
• Traces matter: Targeted optimization of monoclonal antibody N‐glycosylation based on/by implementing automated high‐throughput trace element screening

  2020cites this paper
• Accelerating Biologics Manufacturing by Modeling: Process Integration of Precipitation in mAb Downstream Processing

  2020cites this paper
• Functional analysis of glycosylation in Etanercept: Effects over potency and stability.

  2020cites this paper
• Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases

  2020cites this paper
• Mechanistic and Statistical Modelling of Bioprocesses

  2020cites this paper
• High-resolution mapping of glycoprotein structure-activity relationships by shotgun scanning glycomutagenesis

  2020cites this paper
• Modeling the Effect of Amino Acids and Copper on Monoclonal Antibody Productivity and Glycosylation: A Modular Approach

  2020cites this paper
• Clinical- and Commercial-Scale Reactors

  2020cites this paper
• Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins

  2020cites this paper
• The Best IgG Subclass for the Development of Therapeutic Monoclonal Antibody Drugs and their Commercial Production: A Review

  2020cites this paper
• The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation.

  2020cites this paper
• Abstracts from the 26th European Society for Animal Cell Technology Meeting - Cell culture technologies: bridging academia and industry to provide solutions for patients

  2020cites this paper
• Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid

  2020cites this paper
• The hydrophilic boronic acid-poly(ethylene glycol) methyl ether methacrylate copolymer brushes functionalized magnetic carbon nanotubes for the selective enrichment of glycoproteins.

  2020cites this paper
• Stable Protein Sialylation in Physcomitrella

  2020cites this paper
• Design and Optimisation of Mammalian Cell Perfusion Cultures

  2020cites this paper
• Scale-Down Models and Sensors for Process Development

  2020cites this paper
• Perfusion Bioreactors:The Set-Up and Process Characterisation

  2020cites this paper
• Perfusion Mammalian Cell Culture for Recombinant Protein Manufacturing

  2020cites this paper
• The sialylation profile of IgG determines the efficiency of antibody directed osteogenic differentiation of iMSCs by modulating local immune responses and osteoclastogenesis.

  2020cites this paper
• Future Science Group

  2019cites this paper
• Expression, Role, and Regulation of Neutrophil Fcγ Receptors

  2019cites this paper
• Differentiation of focal autoimmune pancreatitis from pancreatic ductal adenocarcinoma

  2019cites this paper
• IgG Glycans as a Biomarker of Biological Age

  2019cites this paper
• Process intensification for the production of rituximab by an inducible CHO cell line

  2019cites this paper
• Therapeutic protein purity and fragmented species characterization by capillary electrophoresis sodium dodecyl sulfate using systematic hybrid cleavage and forced degradation

  2019cites this paper
• Special Section on Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities — Minireview Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides

  2019cites this paper
• Glycoengineering of Antibodies for Modulating Functions.

  2019cites this paper
• In vitro and in vivo efficacy of anti‐chikungunya virus monoclonal antibodies produced in wild‐type and glycoengineered Nicotiana benthamiana plants

  2019cites this paper
• Activity Determination of Glycosyltransferases.

  2019cites this paper
• High accuracy differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma by immunoglobulin G glycosylation

  2019cites this paper
• Antibody conjugation and formulation

  2019cites this paper
• Comprehensive analysis of human IgG Fc N-glycopeptides and construction of a screening model for colorectal cancer.

  2019cites this paper
• Antibody and antibody derivatives as cancer therapeutics.

  2019cites this paper
• Antibody Structure and Function: The Basis for Engineering Therapeutics

  2019cites this paper
• Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides

  2019cites this paper
• Engineering the genome of Escherichia coli BL21 for improved secretory production of recombinant proteins

  2019cites this paper